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Introduction
Currently, 5.3 million Americans are living with Alzheime~s disease
(AD). 1 AD is the most common cause of dementia and causes up to 5080 percent of dementia cases according to the National Institute on Aging. 2The disease is named after Dr. Alois Alzheimer, who first described
amyloid plaques and neurofibrillary tangles. Neurofibrillary tangles begin
to form in the entorhinal cortex and, along with plaque development in
other areas of the brain, lead to neuronal damage, eventually causing
malfunction and death of the neuron. Damage to the brain begins 10 to
20 years before onset of symptoms. The damage eventually spreads
to the hippocampus, and, as the extent of damage and neuron death
increases, the size of the brain decreases.

ing on the cause of the disease rather than treating the symptoms and
progression of the disease after onset.2

New Approaches
In a normally functioning brain, glucose is the primary energy source,
and the contribution made by fatty acids is considered small. 4 Glucose
undergoes aerobic oxidation to form carbon dioxide and water. In a brain
with AD, a decrease in the cerebral metabolic rate of glucose (CMRglu) is observed early on in the process. This disturbance is known as
glucose hypometabolism and has been found to occur in some patients
decades before the symptoms of AD develop. Because hypometabolism
occurs early and is progressive, it is a reasonable target in the treatment
of AD, with a therapeutic goal of increasing the neuronal energy state.
One way to reach this goal would be to maintain elevated glucose levels
by using insulin sensitizers and, in some cases, insulin. However, this
method is associated with significant risks, such as hypoglycemia and
the lack of compliance of the patient population causing investigations
into alternative energy sources.

Although the cause of AD is still unclear, scientists have identified
several probable causes, including genetic, environmental and lifestyle
factors. 2Familial AD is caused by mutations on certain chromosomes,
which results in the formation of abnormal amyloid precursor protein
(APP), the precursor for beta-amyloid. Other genetic mutations increase
the amount of beta-amyloid formed, which accumulates to form plaques.
Another genetic risk factor, SORL 1, was discovered in 2007 and is
responsible for the transportation of APP within cells. When present
at low levels, the levels of beta-amyloid increase, increasing the harm
to neurons. Current research on AD is focusing on the link between
cognitive decline and heart disease, high blood pressure, diabetes and
obesity. One theory examines decreased blood flow to the brain associated with high blood pressure and high cholesterol. This may result in
decreased glucose metabolism and an increase in BACE1, the enzyme
that cleaves APP, thus causing beta-amyloid deposition. 3 Scientists
also are investigating lifestyle factors that may improve the outcome
and progression of patients with AD. The National Institute on Aging
recommends a nutritious diet, exercise, social engagement and mentally
stimulating pursuits as lifestyle factors that might help reduce the risk of
cognitive decline and AD.2

Ketone bodies cause hyperketonemia, which can be safely induced and
maintained for several hours compared to hypoglycemia. Ketone bodies
readily cross the blood brain barrier and are metabolized by neurons.
For decades, ketogenic diets have been used in epilepsy and Parkinson's disease as a way to decrease blood glucose levels and increase
ketone bodies. These diets normally consist of 88 percent fat, 1Opercent
protein and 2 percent carbohydrates. When used in the management of
seizures, 53.9 percent of patients had more than a 75 percent reduction
in seizures one month after starting the diet. Parkinson's patients using
this type of diet also showed improvement in motor scores in patients
with increased ketone levels after 28 days. Although the diet showed
improvements in these central nervous system diseases, it is impractical
for chronic use because of the high fat intake, high number of calories
and an unpalatable regimen.

Current Treatment
Four drugs are currently indicated for the treatment of AD: donepezil
(Aricept®), rivastigmine (Exelon®), galantamine (Razadyne®) and
memantine (Namenda®). These drugs assist in controlling neurotransmitter release, which may decrease symptoms, but do not treat the
underlying cause of AD. 2Donepezil, rivastigmine and galantamine are
acetylcholinesterase inhibitors. Inhibiting acetylcholinesterase increases
the amount of acetylcholine available to neurons in the brain. 1 Acetylcholine is important for learning and memory. The disease destroys cells
that synthesize and use acetylcholine. Donepezil is approved to treat
all stages of the disease, whereas rivastigmine and galantamine are
approved to treat mild to moderate AD. Memantine works by regulating
glutamate activity and is approved for treatment of moderate to severe
AD. Current treatment is aimed at maintaining cognitive function and
slowing the progression of the disease. However, new research is focus-

Caprylldene
One of the major ketone bodies in humans is beta-hydroxybuterate
(BHB). The main benefit of BHB is its conversion to acetoacetate (ACA)
in the mitochondria. This generates a reducing equivalent of NADH,
which increases energy in this redox couple. Conversion of ACA to
acetyl-CoA then generates succinate, a substrate for complex II, which
allows for possible bypass of complex I inhibition. BHB also increases
acetyl-CoA levels in the mitochondria. The end result of having increased ketone levels is improvement of mitochondrial efficiency and
a decrease in the number of reactive oxygen species produced. For
these reasons, the new drug caprylidene, which is an orally administered
medium-chain triglyceride, is being used in the treatment of hypometabolism in AD. Caprylidene is metabolized by the liver to the active
ketone bodies BHB and ACA, providing an alternative energy source for
the brain. Clinical trials of capylidene in patients with cognitive impair-
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ments that have been completed to date have proven that elevation in
plasma BHB levels with an oral dose can improve memory and attention performance in individuals with memory and cognitive impairment.
Caprylidene appears to be a safe method to elevate plasma levels of
ketone bodies.
Caprylidene is a medical food dispensed by prescription only that
contains a formulation of medium chain triglycerides (MCTs). A medical food is defined as "a food which is formulated to be consumed or
administered enterally or orally under the supervision of a physician,
and which is intended for the specific dietary management of a disease
or condition for which distinctive nutritional requirements, based on
recognized scientific principles, are established by medical evaluation."5
Caprylidene contains a formulation of caprylic triglyceride, which is an
MCT for the clinical dietary management of the metabolic processes
associated with mild to moderate AD. 6 Patients should take 40 grams
(one full packet) mixed in liquid once a day after breakfast or lunch. The
most common adverse effects reported by patients in clinical studies
were gastrointestinal in nature. Most reported were nausea, abdominal
discomfort and diarrhea.
This medical food was tested in trials that allowed subjects to remain
on their prescribed medications for AD as long as they had been on a
stable dose for at least three months. Most of the patients in these trials
were receiving other medications for AD, including acetylcholinesterase
inhibitors and/or NMDA receptor antagonists. It was determined that
caprylidene can be administered as adjunctive therapy along with other
AD medications. Caprylidene contains milk and soy, so it should not
be used in patients that are allergic to either of these products. It also
should be used with caution in patients with known hypersensitivity
to palm or coconut oil and in patients at risk for ketoacidosis, such as
alcoholics and uncontrolled diabetics. Also, elevated triglyceride levels
were observed in patients who presented with probable metabolic
syndrome; therefore, triglyceride levels should be monitored in patients
with metabolic syndrome. 6
In a double-blind, placebo-controlled clinical trial, researchers tested
the hypothesis that acute elevation of serum f3-hydroxybutyrate
(f3-0HB) levels through an oral dose of MCTs would improve memory
and attention in individuals with AD or mild cognitive impairments. 7
f3-0HB is a type of ketone body that appears to protect hippocampal
neurons. The cognitive differences were examined between subjects
with and without the APOE-e4 allele. Missing this allele is a genetic risk
factor of sporadic AD. Results demonstrated that there was an increase
in the Alzheimer's Disease Assessment Scale-Cognitive Subscale
(ADAS-cog) within the e4- group (P=0.04).

in AD patients and thus resulted in significant differences in ADAS-Cog
scores compared to placebo.
Patients and their caregivers should be advised that mild GI symptoms
may occur with caprylidene and should be taken following a meal
containing fats and proteins so that the digestion of the MCTs occurs
more slowly. Sipping the drink over a period of 30 minutes can improve
tolerability rather than drinking it all at once. Some patients may require
starting at a lower dose (~2 tbsp) and tapering up to a full dose. Also,
over-the-counter medications such as simethicone, antacids and antidiarrheals can be useful for treating GI symptoms that may occur.
Caprylidene is a novel therapeutic strategy because it treats one of the
underlying causes of AD instead of treating the symptoms and progression of the disease. Because caprylidene is a safe treatment option with
few side effects and no interactions with other AD medications, it can
be initiated at almost any point in the treatment of AD depending on the
physician's recommendations. In order for a patient to use caprylidene,
they need to get a prescription from their physician and bring it into their
pharmacy to be filled. Because this drug is so new, and in a relatively
new class, further studies need to be conducted to prove the long-term
efficacy of the medication and to solidify caprylidene's place in the treatment of AD.
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A randomized, double-blind, placebo-controlled, parallel-group study
tested the hypothesis that ketosis could improve cognitive performance
in AD. Clinicians administered a ketogenic compound to 152 patients
with mild to moderate AD. 8 The results demonstrated that, in the
population that was missing the APOE- e4 allele, there was a significant difference in ADAS-Cog scores versus placebo on two different
instances (p=0.005 and p=0.0148). It was determined that the ketogenic compound that was studied rapidly elevated serum ketone bodies
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